SUGAMMADEX Drug Patent Profile
✉ Email this page to a colleague
When do Sugammadex patents expire, and when can generic versions of Sugammadex launch?
Sugammadex is a drug marketed by Aspiro, B Braun Medical, Dr Reddys, Fresenius Kabi Usa, Gland, Hikma, Lupin, Mankind Pharma, MSN, Mylan, Qilu Pharm Hainan, Sandoz, Steriscience, Sun Pharm Inds Inc, Tamarang, Teva Pharms Usa Inc, Zenara, and Zydus Pharms. and is included in nineteen NDAs.
The generic ingredient in SUGAMMADEX is sugammadex sodium. There is one drug master file entry for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the sugammadex sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sugammadex
A generic version of SUGAMMADEX was approved as sugammadex sodium by ASPIRO on June 9th, 2023.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SUGAMMADEX?
- What are the global sales for SUGAMMADEX?
- What is Average Wholesale Price for SUGAMMADEX?
Summary for SUGAMMADEX
| US Patents: | 0 |
| Applicants: | 18 |
| NDAs: | 19 |
| DailyMed Link: | SUGAMMADEX at DailyMed |
US Patents and Regulatory Information for SUGAMMADEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zenara | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214306-001 | Jul 28, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Tamarang | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 215260-001 | Jul 28, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Zenara | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214306-002 | Jul 28, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Tamarang | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 215260-002 | Jul 28, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Aspiro | SUGAMMADEX SODIUM | sugammadex sodium | SOLUTION;INTRAVENOUS | 214337-001 | Jun 9, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
